We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

50 hedge funds and large institutions have $21.9M invested in Tempest Therapeutics in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

6% more funds holding

Funds holding: 47 → 50 (+3)

21% less capital invested

Capital invested by funds: $27.9M → $21.9M (-$5.97M)

62% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 13

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
5
Reduced
13
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M
2
Deutsche Bank
Deutsche Bank
Germany
+$734K
3
BCM
Bridgeway Capital Management
Texas
+$575K
4
LCM
Laurion Capital Management
New York
+$474K
5
Two Sigma Investments
Two Sigma Investments
New York
+$348K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$4.99M
2
ACA
Avoro Capital Advisors
New York
-$1.59M
3
GC
GMT Capital
Georgia
-$1.14M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$562K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$365K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$97K -$4.2K -1 -4%
Goldman Sachs
27
Goldman Sachs
New York
$97K +$101K +24 New
HCM
28
Howland Capital Management
Massachusetts
$88K – – –
AL
29
AJO LP
Pennsylvania
$86K +$88.1K +21 New
Two Sigma Advisers
30
Two Sigma Advisers
New York
$60K +$63K +15 New
OC
31
Oppenheimer & Co
New York
$56K -$16.8K -4 -22%
ARTA
32
A.R.T. Advisors
New York
$51K -$42K -10 -43%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$50K +$4.2K +1 +9%
TSS
34
Two Sigma Securities
New York
$48K +$50.4K +12 New
Russell Investments Group
35
Russell Investments Group
United Kingdom
$39K +$37.8K +9 New
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$38K – – –
State Street
37
State Street
Massachusetts
$29K – – –
SKK
38
Shepherd Kaplan Krochuk
Massachusetts
$28K -$16.8K -4 -36%
GC
39
Guggenheim Capital
Illinois
$16K – – –
SIP
40
Stoneridge Investment Partners
Pennsylvania
$14K -$4.2K -1 -25%
UBS Group
41
UBS Group
Switzerland
$14K – – –
Citigroup
42
Citigroup
New York
$8K – – –
Macquarie Group
43
Macquarie Group
Australia
$8K +$8.39K +2 New
MAM
44
Meeder Asset Management
Ohio
$7K – – –
TIM
45
Tortoise Investment Management
New York
$5K – – –
Morgan Stanley
46
Morgan Stanley
New York
$4K -$37.8K -9 -90%
MA
47
MUFG Americas
New York
$4K – – –
Federated Hermes
48
Federated Hermes
Pennsylvania
$3K – – –
LTFS
49
Ladenburg Thalmann Financial Services
Florida
$3K +$4.2K +1 New
TCOV
50
Trust Company of Vermont
Vermont
$2K – – –
1
2
3

TPST Hedge Fund Activity: Q4 2017 in Review

50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2017, worth a combined $21.9M — down 21% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TPST positions and 10 closed out — a net gain of 3 holders — while 5 added to existing stakes and 13 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.99M sold.

  • 50 institutional investors held Tempest Therapeutics (TPST) as of Q4 2017, up from 47 in Q3 2017.
  • Funds reported $21.9M of Tempest Therapeutics stock for Q4 2017, down 21% quarter-over-quarter.
  • 13 funds opened new Tempest Therapeutics positions in Q4 2017 and 10 closed out, a net change of +3 holders.
  • The largest Tempest Therapeutics buyer in Q4 2017 was Renaissance Technologies, an estimated $1.1M added.
  • The largest Tempest Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $4.99M sold.

Based on aggregated 13F filings for Q4 2017.